Primary Market :
Human Health
Solvay companies are front runners in psychotropic treatments, gastro-intestinal drugs and enzymes, laxatives and hormone replacement therapy.
Solvay Pharmaceutical’s strategy has made it a leader in a small and carefully selected range of fields. Development is concentrated on indications for which clinical need for treatment is most urgent and where Solvay feels it has an innovative contribution to make.
Research and production are therefore centered on the following areas of medical treatment: psychiatry, gastroenterology, gynecology and cardiology.
New drugs developed by Solvay’s researchers, new formulations and licensing agreements will extend the range of treatments available worldwide.
| SELECTED INDICATIONS | TRADEMARKS | PRODUCTS |
|---|---|---|
| Pharmaceuticals (not all production indications are offered in all countries) | ||
| Psychiatry | ||
| Anti-depressant; treatment of Obsessive Compulsive Disorders | LUVOX FAVERIN FEVARIN FLOXYFRAL DUMIROX |
fluvoxamine (selective serotonin reuptake inhibitor) |
| Treatment of manic depressive disorder | LITHOBID | lithium carbonate s.r. |
| Anti-vertigo, micro-granulation | BETASERC SERC |
betahistine |
| Cardiology | ||
| Hypertension
|
PHYSIOTENS FOSINIL TEVETEN® ACEON |
moxonidine fosinopril eprosartan perindopril |
| Hormone Replacement Therapies | ||
| Gynaecology
Menopausal symptoms, osteoporosis “See also the Solvay Menopause (in English) and the Menoweb (in French) sites”. Dysmenorrhea |
ESTRATAB PRESOMEN ZUMENON |
estrogens |
| ESTRATEST | estro-testosterone, testosterone | |
| DUPHASTON PROMETRIUM |
dydrogesterone progestogens |
|
| Gastroenterology | ||
| anti-ulcer | PANTOLOC | pantoprazole |
| Hepatic coma, constipation | BIFITERAL DUPHALAC |
lactulose |
| Pancreatic deficiencies: especially cystic fibrosis and chronic pancreatis | CREON | lipases, amylases and proteases |
| Irritable bowel syndrom | DUSPATAL DUSPATALIN |
mebeverine |
| Inflammatory complaints of the colon | DICETEL | pinaverine |
| ROWASA | ||
| Others | ||
| Flu vaccine | INFLUVAC | vaccine |
Geographic breakdown of sales in 1999
(Total sales: EUR 1,349 million)
European Union 44 % Other European Countries 10 % Nafta 38 % Mercosur < 1 % Africa – Middle-East 4% Asia – Pacific (including Japan) 4%
Pharmaceutical Sector Contact Addresses